Pharma Mar SA (ES:PHM) has released an update.
Pharma Mar S.A. has announced that the European Commission has revoked a previous decision which had denied marketing authorization for the company’s medicinal product ‘Aplidin – plitidepsin.’ This revocation follows a legal re-evaluation that identified a potential conflict of interest involving an expert who participated in the initial authorization process. The European Medicines Agency has been directed to re-examine the drug’s marketing authorization application.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.
